A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (NCT01871727), a na phase 3 study. The primary outcome is Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

2. Clinical Question

The broader stated purpose was to assess E7777 efficacy and safety in recurrent or persistent CTCL. Objective response rate was named in the trial summary as the efficacy measure for Stage I - III participants. The record also lists secondary measures of response duration, time to response, investigator-assessed ORR, ORR assessed by an independent review committee, treatment-emergent adverse events, serious adverse events, and maximum serum concentration in the lead-in.

These objectives cover different clinical and statistical questions. A dose-limiting toxicity count in the lead-in concerns tolerability under a specified set of toxicity criteria during a defined treatment period. ORR concerns whether participants meet criteria for an objective response, while response duration and time to response address timing and persistence. The registry record names these outcomes but does not report their numerical results in the information available for this analysis. Therefore, the trial's design and endpoint definitions can be described, but the size or precision of any efficacy effect cannot be assessed from this record.

3. Trial Design

This was a Phase 3, single-group study of E7777 in persistent or recurrent cutaneous T-cell lymphoma. The registry lists enrollment of 112 participants and describes the study as completed. Its stated start date is 2013-05-30, and its primary completion date is 2021-12-06. These dates describe the registry record and do not establish when results were analyzed or reported.

The study had a lead-in dose-finding part and a main study part. The summary says that the lead-in was used to determine the 9 mcg/kg dose for testing efficacy and safety. The safety groups listed for the lead-in include E7777 at 6 mcg/kg, 12 mcg/kg, and 15 mcg/kg; a separate listed group combines the lead-in and main study parts at 9 mcg/kg. This structure means the dose groups do not serve as randomized parallel controls. In particular, results across the groups could reflect differences in study part, participant composition, or other features, not only dose.

The masking field is NONE, and the allocation field is NA. The record therefore describes an unmasked, nonrandomized, single-group design rather than a blinded comparison against a control treatment. It does not report a concurrent comparator. The listed primary endpoint is a lead-in safety count, whereas the trial summary emphasizes ORR as an efficacy measure for the main study purpose. That distinction matters: the primary endpoint named in the registry is not itself a direct estimate of comparative efficacy.

The record lists 29 outcome measures and no analyses. It does not report the protocol's detailed statistical plan, the rationale for the planned enrollment, or whether interim analyses were planned. These items should not be inferred from the Phase 3 label or from the total enrollment. The registry describes the objectives, study structure, and several outcome definitions, but does not provide the primary endpoint result needed to interpret the trial's lead-in dose-limiting toxicity count.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 36 participants were screened in Lead-In Part, out of which 21 were enrolled and treated.143 participants were screened in Main Study Part, out of which 91 were enrolled and 90 were treated. As per planned analysis, data was collectively reported for total 98 participants (Full analysis set/Safety analysis set) from Main Study Part and Lead-In Part who received study drug at 9 micrograms per kilograms (mcg/kg) dose. 8 participants were from Lead-In Part and 90 were from Main Study Part.

Lead-In Part (1 Year 2 Months)

Reasons for not completing this period:

Main Study Part (2 Years 4 Months)

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Lead-in analysis set included all participants enrolled in lead-in part.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Lead-In Part: Safety Analysis Set (SAS) included all participants who received study drug. Main Study Part: SAS included all participants (both Main Study and Lead-In) who received study drug at 9 mcg/kg. As per planned analysis baseline data was collected and reported for 98 participants who received 9 mcg/kg dose in lead-in and main study part.

6. Primary Endpoint

The registry lists the primary outcome as Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03), measured over Cycle 1 (cycle length was 21 days).

The listed primary endpoint is the number of lead-in participants with dose-limiting toxicities (DLTs) under NCI CTCAE v4.03 during Cycle 1, with a cycle length of 21 days. Its population is all participants enrolled in the lead-in part. It is a count of participants meeting the specified toxicity definition, not a continuous measure of symptom severity or a comparative treatment effect.

The definition includes specified serious infusion reactions, capillary leak syndrome meeting the stated criteria, clinical visual impairment, certain severe adverse events that may represent an infusion reaction, and other toxicities judged treatment-related and dose-limiting by a safety consultancy investigator panel. The record describes infusion reactions as symptoms occurring within 24 hours of E7777 infusion. For the capillary leak definition, the listed findings are hypotension, edema, or serum albumin < 3.0 g/dL, with at least 2 of those findings required. It also states the relevant CTCAE grades and exceptions.

A DLT endpoint is used in dose-finding because it focuses on treatment-emergent toxicities considered important for dose selection. It gives a defined safety question tied to a specified treatment period and criteria. However, a count alone does not convey the full range, duration, or clinical context of adverse events; those require additional safety outcomes and detailed reporting. The registry record does not report how many lead-in participants met the DLT definition. The endpoint's definition can therefore be explained, but its observed result cannot be interpreted from the registry information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The appropriate statistical reading starts with the design. This is a single-group study without random allocation or masking, not a randomized trial with a concurrent control arm. The lead-in dose groups are part of the study's dose-finding structure, and the 9 mcg/kg safety group combines participants from the lead-in and main study parts. A contrast among these groups is not equivalent to a randomized dose comparison. Differences in the participants, study period, or study procedures could accompany the different dose levels.

What does a participant count represent?

The primary endpoint is a count of participants meeting a defined DLT criterion in the lead-in analysis set during Cycle 1. Such a count is useful as a direct description of how many participants met the study's operational definition. A count does not, by itself, describe uncertainty around the underlying frequency. For that, an analysis would generally pair the count with its denominator and an appropriate interval estimate. The registry record does not report the primary endpoint count or an interval estimate, so those features cannot be evaluated.

The toxicity definition is composite: it includes several types of events and CTCAE severity conditions. That makes the endpoint responsive to more than one kind of potential toxicity, but it also means that participants could meet the endpoint for different clinical reasons. Interpretation depends on the stated criteria, the assessment period, and consistent event adjudication. The record describes the criteria and names a safety consultancy investigator panel for certain toxicities; further details of adjudication procedures are not reported in the registry record.

Why does the design matter for interpretation?

Randomization, when used, helps make groups comparable by distributing known and unknown baseline factors across assigned treatments. This trial's allocation is listed as NA and its model as single-group. No such randomized balancing is available for comparisons between the listed dose groups. A numerical difference between dose groups, even if one were reported, could reflect participant or study-part differences as well as dose. The registry explicitly warns that the arms are not a like-for-like control comparison.

Masking is listed as NONE. In an unmasked study, participants and study personnel know the treatment assignment. This can matter particularly for outcomes involving clinical judgments, such as the assessment of response or attribution and classification of adverse events. The listed main-study response assessments include independent review committee assessment, which can provide a distinct assessment process; the registry record does not report the detailed blinding or adjudication arrangements for that review. It is not appropriate to assume further protections that are not described.

How should safety counts be read?

The serious adverse event and other adverse event figures are counts of participants affected, alongside counts at risk for each group. These categories are not interchangeable with the DLT endpoint. A serious adverse event classification is not, by itself, proof that the event met the DLT criteria, was attributed to E7777, or occurred during Cycle 1. Similarly, the number of participants with other adverse events does not indicate how many distinct events occurred, how severe they were, or how long they lasted. The posted group summaries should be read as descriptive safety information, not as adjusted comparisons.

Deaths are listed separately in the group summaries. The record does not specify in this information whether the deaths were treatment-related, when they occurred, or how they were adjudicated. The counts therefore describe what is listed in the registry, not causation. More detailed narratives and follow-up information would be needed to characterize the circumstances.

What do confidence intervals and significance tests add?

In general, a confidence interval expresses the statistical uncertainty around an estimate under the assumptions of the analysis. A narrow interval indicates greater precision, while a wide interval indicates less precision. For an event count or response proportion, an interval is meaningful only alongside a clearly defined population, endpoint, and denominator. A significance test addresses a different question: how compatible the observed data are with a specified null model. Neither an interval nor a p-value substitutes for effect size, endpoint context, or study design.

The registry record lists no analyses and supplies no primary endpoint estimate, efficacy estimate, confidence interval, or p-value in the information. Statistical significance therefore cannot be assessed. General concepts about intervals and tests explain how such results would be read if reported; they do not fill in missing trial results.

How should planning illustrations be distinguished from trial evidence?

A sample-size illustration based on an observed effect is not the trial's original design justification and does not establish observed power. The stated illustration assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. Time-to-event illustrations use a total event count, while other illustrations use participants per arm. Those are hypothetical planning conventions, not a description of this single-group study's allocation or evidence of its achieved power. The registry record does not report the original sample-size justification, and no values for an observed effect or planning illustration are reported in the registry information.

Over-dispersion is a general concern when observed variability exceeds the assumptions of a simple statistical model; ignoring it can make uncertainty appear too small. Its relevance depends on the outcome and model. The registry record does not report a model or analysis for which over-dispersion was assessed, so it cannot be said whether this issue affected the trial's estimates.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Lead-In Part: E7777 6 mcg/kg", "Lead-In Part: E7777 9 mcg/kg", "Lead-In Part: E7777 12 mcg/kg", "Lead-In Part: E7777 15 mcg/kg")
n      <- c(2, 8, 9, 2)
events <- c(0, 0, 0, 2)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Lead-In Part: E7777 6 mcg/kg  2  0  0.0  0.0  84.2  0.0  65.8  0.8  70.8
ARM  Lead-In Part: E7777 9 mcg/kg  8  0  0.0  0.0  36.9  0.0  32.4  0.3  33.6
ARM  Lead-In Part: E7777 12 mcg/kg  9  0  0.0  0.0  33.6  -0.0  29.9  0.3  30.8
ARM  Lead-In Part: E7777 15 mcg/kg  2  2  100.0  15.8  100.0  34.2  100.0  29.2  99.2

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 29 outcome measures, including the primary DLT count and several secondary response and safety outcomes. When a study examines many outcomes, the chance of obtaining an apparently notable result somewhere among them can increase. A prespecified testing hierarchy or other multiplicity strategy can help explain which tests are confirmatory and how conclusions should be calibrated. The statistical plan for handling multiplicity is not reported in the registry record. The list of outcomes alone does not establish which were formally tested, which were exploratory, or whether adjustment was used.

The record lists no analyses. It does not report the primary endpoint result, the numerical efficacy results, the analysis populations used for those outcomes, or the methods used to handle missing outcome data. Missingness can affect interpretation if participants without an assessment differ from those assessed, or if the reasons for missing data relate to outcomes. Without the amount, timing, and handling of missing data, the direction or magnitude of any resulting bias cannot be determined.

The primary endpoint specifies a lead-in analysis set that includes all participants enrolled in the lead-in part. This definition identifies the intended population for that endpoint, but does not report the number analyzed or how incomplete safety observation was handled. The record also names investigator and independent-review assessments for response outcomes, but does not describe the analysis populations or missing-assessment rules in the information.

These omissions limit statistical interpretation. No protocol, analysis plan, interim-analysis schedule, multiplicity adjustment, or missing-data approach should be inferred. The registry record gives outcome definitions and some descriptive safety figures, but not enough analysis detail to establish how the full set of outcomes was handled.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: capillary leak syndrome (100.0%), atrial fibrillation (50.0%), dehydration (50.0%), vomiting (22.2%), anaemia (11.1%).

The serious adverse event summaries list the number at risk and the number affected for each dose group. At 6 mcg/kg, 2 participants were at risk and 0 were listed as affected by serious adverse events. At 12 mcg/kg, 9 were at risk and 4 were affected; at 15 mcg/kg, 2 were at risk and 2 were affected. In the group combining the lead-in and main study parts at 9 mcg/kg, 98 were at risk and 36 were affected. The record also lists deaths for each group: 0, 3, 0, and 13, respectively.

These figures are descriptive and do not establish that E7777 caused a serious adverse event or death. The group sizes differ, the groups are not randomized controls, and the 9 mcg/kg group combines study parts. Serious adverse events are also distinct from the primary DLT endpoint, which uses specific criteria and a Cycle 1 assessment period. The registry record does not state whether the listed deaths were treatment-related or provide their timing and circumstances.

The separate counts for other adverse events indicate participants affected, not the total number of events or their severity distribution. Term-level percentages are listed for several serious adverse event terms, but the relevant denominators are not reported in the registry record.

13. What the Result Does, and Does Not, Mean

The registry record describes a Phase 3 study with a lead-in dose-finding part and a main study part, focused on persistent or recurrent CTCL. It states that 9 mcg/kg was selected in the lead-in for testing efficacy and safety. The record also lists safety counts across dose groups and defines a lead-in DLT endpoint. Those details characterize the study's structure and the kinds of outcomes collected.

They do not establish the trial's primary endpoint result. The registry record does not report the number of lead-in participants with DLTs, although that is the named primary endpoint. Nor does it report numerical ORR results or the estimates and uncertainty needed to assess response outcomes. It is therefore not possible to describe the magnitude or precision of an efficacy effect from the information.

The safety counts should not be interpreted as causal treatment effects. There is no concurrent control group, and the dose groups are not randomized like-for-like comparisons. Counts across groups can be influenced by their different sizes and by differences in study part or participants. Listed deaths are not identified as treatment-related; they should not be described as caused by E7777.

More generally, a registry outcome definition is not a result, and an observed count without suitable context does not answer every question about risk. Interpretation of safety and efficacy depends on the relevant population, outcome criteria, assessment period, analysis methods, and uncertainty. Several of these details, including results for the primary endpoint and analysis plans, are not reported in the registry record. The sound conclusion is limited to describing the design and posted data, not making a treatment recommendation or a definitive claim about benefit or harm.

14. Why This Trial Matters Statistically

This trial illustrates why endpoint labels and study structure need to be read together. The study summary emphasizes ORR as an efficacy objective, while the registry's named primary endpoint is a lead-in count of participants with DLTs during Cycle 1. These outcomes answer different questions. A DLT count informs a defined safety and dose-finding question; ORR is an efficacy outcome. Neither can stand in for the other.

The lead-in and main study parts also make the analysis population important. The primary endpoint applies to participants enrolled in the lead-in, whereas the listed 9 mcg/kg safety group combines the lead-in and main study parts. Knowing which participants contribute to each outcome is essential before relating a result to a dose or study objective. The record's group structure does not support treating the dose rows as randomized comparisons.

The trial is also a useful example of the boundary between design information and evidence about outcomes. The record gives a detailed DLT definition and descriptive safety counts, but does not report the primary endpoint count or numerical efficacy results in the information. Without estimates and measures of uncertainty, statistical precision cannot be judged. Without a concurrent control, comparative efficacy or comparative safety cannot be established from this design alone.

Finally, a large list of outcomes increases the importance of a transparent statistical plan. Multiplicity, missing-data handling, analysis populations, and any interim analyses can affect how findings should be interpreted. The registry record does not report these details. Recognizing what the record does and does not document is a core part of rigorous statistical reading: it prevents descriptive data from being mistaken for a causal effect or an unreported result from being assumed.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most immediate limitation is that the registry record does not report the numerical result for the listed primary endpoint. It also does not report numerical results for the efficacy outcomes named in the study summary and secondary outcome list. Consequently, this analysis cannot characterize the observed DLT count, ORR, response duration, or time to response, or assess their precision.

The single-group design has no concurrent control arm and no random allocation. It cannot provide a randomized estimate of the difference between E7777 and another treatment. The dose groups are not like-for-like controls, and the 9 mcg/kg safety group combines lead-in and main study participants. Comparisons among the dose rows are therefore descriptive and may reflect differences other than dose.

Masking is listed as NONE. The record does not provide detailed information about how outcomes were assessed beyond naming investigator and independent review committee assessments. It also does not report the statistical analysis plan, sample-size justification, interim-analysis plan, missing-data methods, multiplicity strategy, or full analysis populations. These omissions limit evaluation of the risk of bias and the robustness of any results.

The safety summaries do not provide event narratives, timing, attribution, or a detailed breakdown of severity for the listed participant counts. Deaths are listed, but their relationship to treatment is not reported in the registry information. Term-level serious adverse event percentages are provided without the denominators described in this analysis. These limits preclude more detailed interpretation of the safety profile.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma — NCT01871727.
• Registry record last updated 2024-11-13; status last verified 2022-11.
• Results first posted 2024-11-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a completed Phase 3, single-group, unmasked study of E7777 in persistent or recurrent cutaneous T-cell lymphoma. Enrollment is listed as 112. The study had a lead-in dose-finding part and a main study part; 9 mcg/kg was identified for efficacy and safety testing after the lead-in.

The primary endpoint is the number of lead-in participants with DLTs under NCI CTCAE v4.03 during Cycle 1, whose length was 21 days. The registry record does not report that endpoint's result. It also lists ORR, response duration, time to response, adverse events, serious adverse events, and maximum serum concentration among its outcomes, but numerical efficacy results are not reported in the information.

Descriptive safety counts are listed for lead-in groups at 6 mcg/kg, 12 mcg/kg, and 15 mcg/kg, and for a 9 mcg/kg group combining the lead-in and main study parts. With no randomized comparator and no reported primary endpoint estimate, the posted information supports description of study design and safety counts, not a comparative treatment effect.